Results 231 to 236 of about 9,672 (236)

Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System

Gastroenterology, 2016
George Ioannou, Judith I Tsui, Feng Su
exaly  

Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study

Lancet Infectious Diseases, The, 2016
Tarik Asselah, Didier Samuel
exaly  

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

Lancet Infectious Diseases, The, 2015
Tetsuo Takehara, Naoya Sakamoto, Hirayuki Enomoto   +2 more
exaly  

Spectroflurimetric estimation of the new antiviral agent ledipasvir in presence of sofosbuvir

Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2018
Ahmed El-Olemy, Ebrahim Abolmagd
exaly  

Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study

Lancet Infectious Diseases, The, 2015
Amy K Nelson, Henry Masur, Shyamasundaran Kottilil   +2 more
exaly  

Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection

Gastroenterology, 2014
exaly